Objectives: Understanding the clinical manifestations and management of periodontal disease are important for the optimal care of patients with type 1 diabetes (T1D). Probiotics could protect the oral tissues against the action of periodontal pathogenic bacteria. We aimed to assess the effects of the administration of Lactobacillus reuteri as probiotic upon oral health in children and adolescents T1D. Methods: Forty-three patients (11.32.77 yrs.; T1D duration 58.238.0 months) were enrolled and randomly assigned to Group A (probiotic - 5 drops/day, 10^8 CFU/day for 3 months) and Group B (no probiotic). Oral health index [Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS)], insulin dose (IU/kg/day), and HbA1c were measured at baseline (T0) and 3-months after (T1). Results: FMPS significantly improved in both Group A and B (p<0.05). In Group B daily insulin dose increased (p=0.01) and HbA1c improved (p< 0.001) at T1, while in Group A the metabolic control was unchanged. We performed a telephone survey to evaluate the probiotic compliance in Group A. 13 out 22 patients reported a regular probiotic intake (A1), while the other ones used it sporadically (A2). Despite FMPS and FMBS values were not different between groups at T0, they were significantly lower (p< 0.05) in Group A1 respect to Group A2 at T1. FMPS and FMBS longitudinally decreased in Group A1 but not in Group A2. Conclusions: Our preliminary data suggest that 3-months oral administration of probiotic might improve the oral health of children and adolescents with T1D and confirm that glycemic control have also an influence on oral health.
Lactobacillus reuteri oral administration improves periodontal disease in children and adolescents with type 1 diabetes / Predieri, B.; Cenciarelli, V.; Bruzzi, P.; Miceli, Dalila; Bonvicini, F.; Leo, F.; Forabosco, A.; Iughetti, L.. - In: PEDIATRIC DIABETES. - ISSN 1399-5448. - 18:Supplement S25(2017), pp. 91-92. (Intervento presentato al convegno The 43rd Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) tenutosi a Innsbruck nel 18–21 October 2017).
Lactobacillus reuteri oral administration improves periodontal disease in children and adolescents with type 1 diabetes
B. Predieri;V. Cenciarelli;P. Bruzzi;MICELI, DALILA;F. Bonvicini;F. Leo;A. Forabosco;L. Iughetti
2017
Abstract
Objectives: Understanding the clinical manifestations and management of periodontal disease are important for the optimal care of patients with type 1 diabetes (T1D). Probiotics could protect the oral tissues against the action of periodontal pathogenic bacteria. We aimed to assess the effects of the administration of Lactobacillus reuteri as probiotic upon oral health in children and adolescents T1D. Methods: Forty-three patients (11.32.77 yrs.; T1D duration 58.238.0 months) were enrolled and randomly assigned to Group A (probiotic - 5 drops/day, 10^8 CFU/day for 3 months) and Group B (no probiotic). Oral health index [Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS)], insulin dose (IU/kg/day), and HbA1c were measured at baseline (T0) and 3-months after (T1). Results: FMPS significantly improved in both Group A and B (p<0.05). In Group B daily insulin dose increased (p=0.01) and HbA1c improved (p< 0.001) at T1, while in Group A the metabolic control was unchanged. We performed a telephone survey to evaluate the probiotic compliance in Group A. 13 out 22 patients reported a regular probiotic intake (A1), while the other ones used it sporadically (A2). Despite FMPS and FMBS values were not different between groups at T0, they were significantly lower (p< 0.05) in Group A1 respect to Group A2 at T1. FMPS and FMBS longitudinally decreased in Group A1 but not in Group A2. Conclusions: Our preliminary data suggest that 3-months oral administration of probiotic might improve the oral health of children and adolescents with T1D and confirm that glycemic control have also an influence on oral health.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris